AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7756796 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent positive pressure ventilation
Number of subjects: 29
Study 2334616 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 2 mg kg‐1
Number of subjects: 11
Study 2334616 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 2 mg kg‐1 with adrenaline 1:200,000
Number of subjects: 11
Study 484890 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroprocaine, 3%
Number of subjects: 49
Study 484890 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine, 0.5%
Number of subjects: 49
Study 484890 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroprocaine (1.5%) and Bupivacaine (0.375%) mixture
Number of subjects: 49
Study 30536218 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational curriculum focused on the medical needs of TAY with autism; Intervention group (n=6)
Number of subjects: 14
Study 30536218 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group (WLC); Control group (n=8)
Number of subjects: 14
Study 28535777 — intervention group
Group type: EXPERIMENTAL
Intervention: SFA-reduced, MUFA-enriched dairy product
Number of subjects: 54
Study 26145190 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of tranexamic acid (TXA) 3 g plus diluted epinephrine (DEP) 0.25 mg
Number of subjects: 107
Study 26145190 — intervention group
Group type: COMPARATOR
Intervention: Topical application of tranexamic acid (TXA) 3 g alone
Number of subjects: 107
Study 23307164 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.25 μg/kg
Number of subjects: 60
Study 23307164 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.5 μg/kg
Number of subjects: 60
Study 23307164 — intervention group
Group type: COMPARATOR
Intervention: Normal saline 10 ml
Number of subjects: 60
Study 21930354 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal testosterone spray for 26 weeks
Number of subjects: 9
Study 18281145 — intervention group
Group type: EXPERIMENTAL
Intervention: 10mg vardenafil twice daily
Number of subjects: 0
Study 18281145 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17069951 — intervention group
Group type: EXPERIMENTAL
Intervention: St. John Ambulance online 'crash course' (theoretical course)
Number of subjects: 23
Study 17069951 — intervention group
Group type: COMPARATOR
Intervention: No first aid training (control group)
Number of subjects: 23
Study 12671882 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonoscopy with chromoendoscopy (CE) using 0.1% methylene blue
Number of subjects: 165
Study 12671882 — intervention group
Group type: COMPARATOR
Intervention: Conventional colonoscopy
Number of subjects: 165
Study 11525337 — intervention group
Group type: EXPERIMENTAL
Intervention: True Acupuncture (TA)
Number of subjects: 13
Study 11525337 — intervention group
Group type: COMPARATOR
Intervention: Placebo Needle Application (PA)
Number of subjects: 13
Study 9565508 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon pulmonary valvuloplasty (BPV)
Number of subjects: 9
Study 9565508 — intervention group
Group type: COMPARATOR
Intervention: Control group (no prior BPV)
Number of subjects: 9
Study 7983580 — intervention group
Group type: EXPERIMENTAL
Intervention: Complementarity defined by Carson's model
Number of subjects: 80
Study 7983580 — intervention group
Group type: EXPERIMENTAL
Intervention: Complementarity defined by Kiesler's model
Number of subjects: 80
Study 7983580 — intervention group
Group type: EXPERIMENTAL
Intervention: Complementarity defined by Wiggins's model
Number of subjects: 80
Study 7983580 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral ratings considering base rates
Number of subjects: 80
Study 7983580 — intervention group
Group type: EXPERIMENTAL
Intervention: Friendly antecedent behavior
Number of subjects: 80
Study 7983580 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadrant behavior
Number of subjects: 80
Study 2691477 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxycillin/clavulanate (iv 100 mg/kg/day followed by oral 50 mg/kg/day)
Number of subjects: 64
Study 2691477 — intervention group
Group type: COMPARATOR
Intervention: Benzylpenicillin (100,000 IU/kg/day) + netilmicin (5 mg/kg/day) + metronidazole (30 mg/kg/day) (iv followed by oral metronidazole 30 mg/kg/day)
Number of subjects: 64
Study 2691477 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 64
Study 30802200 — intervention group
Group type: EXPERIMENTAL
Intervention: Ertugliflozin 2.5 mg BID
Number of subjects: 50
Study 30802200 — intervention group
Group type: EXPERIMENTAL
Intervention: Ertugliflozin 7.5 mg BID
Number of subjects: 50
Study 396660 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. pirenzepine infusion (16 mg plus 2 mg/h for 2 hours)
Number of subjects: 19
Study 396660 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 19
Study 31738778 — intervention group
Group type: EXPERIMENTAL
Intervention: Nyström method for approximating leading eigenvalues and eigenvectors in network-based analysis of complex vortical flows.
Number of subjects: 0
Study 31738778 — intervention group
Group type: EXPERIMENTAL
Intervention: Quasi-uniform column sampling
Number of subjects: 0
Study 31738778 — intervention group
Group type: COMPARATOR
Intervention: Uniform column sampling
Number of subjects: 0
Study 29619965 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-infected women receiving curative chemoradiation therapy (CRT)
Number of subjects: 143
Study 29619965 — intervention group
Group type: COMPARATOR
Intervention: HIV-uninfected women receiving curative chemoradiation therapy (CRT)
Number of subjects: 143
Study 29619965 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-infected women receiving curative CRT
Number of subjects: 143
Study 29619965 — intervention group
Group type: COMPARATOR
Intervention: HIV-uninfected women receiving curative CRT
Number of subjects: 143
Study 29619965 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors associated with better 2-year OS
Number of subjects: 143
Study 26777101 — intervention group
Group type: EXPERIMENTAL
Intervention: Video education plus verbal discussion
Number of subjects: 32
Study 26777101 — intervention group
Group type: COMPARATOR
Intervention: Standard verbal discussion alone (control)
Number of subjects: 32
Study 24720679 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT‐450/r-ombitasvir and dasabuvir with ribavirin (150 mg of ABT‐450, 100 mg of ritonavir, 25 mg of ombitasvir, 250 mg dasabuvir twice daily, and 1000 or 1200 mg ribavirin daily)
Number of subjects: 394
Study 24720679 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 394
Study 24720679 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT‐450/r-ombitasvir and dasabuvir with ribavirin
Number of subjects: 394
Study 22948032 — intervention group
Group type: EXPERIMENTAL
Intervention: Monovo® Cream (new formulation of mometasone furoate with 33% water content)
Number of subjects: 20
Study 22948032 — intervention group
Group type: COMPARATOR
Intervention: Ecural® Fettcreme (commercially available fatty cream of mometasone furoate)
Number of subjects: 20
Study 19399203 — intervention group
Group type: EXPERIMENTAL
Intervention: Externally generated feedback
Number of subjects: 26
Study 19399203 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-generated feedback
Number of subjects: 26
Study 19399203 — intervention group
Group type: COMPARATOR
Intervention: No feedback
Number of subjects: 26
Study 17469882 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotherapy
Number of subjects: 153
Study 17469882 — intervention group
Group type: COMPARATOR
Intervention: Medication
Number of subjects: 153
Study 15253174 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive multimedia training program on breast self-examination using a breast model and computer guided feedback on accuracy of lump detection
Number of subjects: 58
Study 15253174 — intervention group
Group type: COMPARATOR
Intervention: National Cancer Institute pamphlet on breast self-examination and breast lumps
Number of subjects: 58
Study 12194635 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone (40 mg)
Number of subjects: 16
Study 12194635 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 9619531 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha‐methyl‐para‐tyrosine (AMPT), 5 x 1 g doses over 26 hours
Number of subjects: 10
Study 9619531 — intervention group
Group type: COMPARATOR
Intervention: Promethazine (active placebo), 5 x 50 mg doses over 26 hours
Number of subjects: 10
Study 7663867 — intervention group
Group type: EXPERIMENTAL
Intervention: PCA morphine plus tenoxicam (20 mg, i.v.)
Number of subjects: 41
Study 7663867 — intervention group
Group type: COMPARATOR
Intervention: PCA morphine only
Number of subjects: 41
Study 2540056 — intervention group
Group type: EXPERIMENTAL
Intervention: Sclerotherapy
Number of subjects: 50
Study 2540056 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 50
Study 1261168 — intervention group
Group type: EXPERIMENTAL
Intervention: Azidomorphine
Number of subjects: 0
Study 31502897 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based, cognitive behavioral programme (n=194)
Number of subjects: 389
Study 31502897 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n=195)
Number of subjects: 389
Study 31319484 — intervention group
Group type: EXPERIMENTAL
Intervention: I2 (5 mg/day) before surgery for 7-35 days
Number of subjects: 60
Study 31319484 — intervention group
Group type: EXPERIMENTAL
Intervention: FEC/TE + I2 after surgery for 170 days
Number of subjects: 60
Study 31319484 — intervention group
Group type: EXPERIMENTAL
Intervention: I2 supplementation before and after surgery
Number of subjects: 60
Study 31319484 — intervention group
Group type: COMPARATOR
Intervention: Placebo (colored water)
Number of subjects: 60
Study 31319484 — intervention group
Group type: COMPARATOR
Intervention: FEC/TE
Number of subjects: 60
Study 31319484 — intervention group
Group type: EXPERIMENTAL
Intervention: FEC/TE + I2 after surgery
Number of subjects: 60
Study 27779896 — intervention group
Group type: EXPERIMENTAL
Intervention: Early neuromuscular blockade
Number of subjects: 0
Study 27779896 — intervention group
Group type: COMPARATOR
Intervention: Control group with sedation
Number of subjects: 0
Study 25597558 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent quality improvement program (Assessing Care of Vulnerable Elders Practice Redesign for Improved Medical Care for Elders)
Number of subjects: 1791
Study 25597558 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1791
Study 23984806 — intervention group
Group type: EXPERIMENTAL
Intervention: Canrenone 50 mg/day for 3 months, then 50 mg b.i.d. until the end of the study
Number of subjects: 145
Study 23984806 — intervention group
Group type: EXPERIMENTAL
Intervention: Canrenone
Number of subjects: 145
Study 21878204 — intervention group
Group type: EXPERIMENTAL
Intervention: Burst-type TENS (pulse width, 200 μs; frequency, 100 Hz; burst frequency, 2 Hz) stimulation over the upper trapezius for 10 minutes
Number of subjects: 76
Study 21878204 — intervention group
Group type: EXPERIMENTAL
Intervention: Burst-type TENS stimulation
Number of subjects: 76
Study 21878204 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (sham-TENS application over the upper trapezius for 10 minutes)
Number of subjects: 76
Study 18703241 — intervention group
Group type: EXPERIMENTAL
Intervention: HeartOp Programme (cognitive-behavioural intervention)
Number of subjects: 204
Study 18703241 — intervention group
Group type: COMPARATOR
Intervention: Routine nurse counselling
Number of subjects: 204
Study 17092457 — intervention group
Group type: EXPERIMENTAL
Intervention: Pediatric constraint‐induced therapy involving constraint of the functional upper extremity and intensive therapy with the hemiparetic upper extremity
Number of subjects: 18
Study 17092457 — intervention group
Group type: COMPARATOR
Intervention: Conventional physical and occupational therapy
Number of subjects: 18
Study 15289633 — intervention group
Group type: EXPERIMENTAL
Intervention: Local indigenous health workers using registers, recall and reminder systems, and basic diabetes care plans, supported by a specialist outreach service.
Number of subjects: 921
Study 11275026 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen therapy
Number of subjects: 62
Study 11275026 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 9303287 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 67
Study 9303287 — intervention group
Group type: EXPERIMENTAL
Intervention: Eltanolone
Number of subjects: 67
Study 8408933 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous salbutamol (10 micrograms/kg)
Number of subjects: 8
Study 8408933 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled salbutamol (100 micrograms, twice)
Number of subjects: 8
Study 2951814 — intervention group
Group type: EXPERIMENTAL
Intervention: Duovent
Number of subjects: 20
Study 2951814 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol
Number of subjects: 20
Study 2951814 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 30760195 — intervention group
Group type: EXPERIMENTAL
Intervention: ω‐3 fatty acids
Number of subjects: 74
Study 30760195 — intervention group
Group type: EXPERIMENTAL
Intervention: nano‐curcumin
Number of subjects: 74
Study 30760195 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of ω‐3 fatty acids and nano‐curcumin
Number of subjects: 74
Study 28371481 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Fear of Movement (BFOM) measure
Number of subjects: 350
Study 28371481 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 350
Study 28371481 — intervention group
Group type: EXPERIMENTAL
Intervention: KOOS ADL
Number of subjects: 350
Study 28371481 — intervention group
Group type: EXPERIMENTAL
Intervention: PHQ-8
Number of subjects: 350
Study 28371481 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-efficacy for exercise (SEE)
Number of subjects: 350
Study 25136856 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambient fine particulate matter (PM2.5) and ozone exposure
Number of subjects: 1218
Study 25136856 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean PM2.5 exposure
Number of subjects: 1218
Study 25136856 — intervention group
Group type: EXPERIMENTAL
Intervention: Lagged exposures to air pollutants
Number of subjects: 1218
Study 25136856 — intervention group
Group type: EXPERIMENTAL
Intervention: Low levels of ambient air pollutants
Number of subjects: 1218
Study 23339313 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotherapy
Number of subjects: 0
Study 23339313 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication
Number of subjects: 0
Study 23339313 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 21047922 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralipid/heparin infusion with 1 mU/min · kg euglycemic insulin clamp
Number of subjects: 22
Study 21047922 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 22
Study 18496366 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin-mediated euglycemia (mean blood glucose, 5.8 +/- 0.4 mmol/L)
Number of subjects: 0
Study 18496366 — intervention group
Group type: COMPARATOR
Intervention: Moderate hyperglycemia (mean blood glucose, 9.6 +/- 0.6 mmol/L)
Number of subjects: 0
Study 17042842 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous granisetron 1 mg
Number of subjects: 960
Study 17042842 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclizine 50 mg
Number of subjects: 960
Study 17042842 — intervention group
Group type: EXPERIMENTAL
Intervention: Both granisetron and cyclizine
Number of subjects: 960
Study 14667179 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapidly hydrolysed starch (R)
Number of subjects: 21
Study 14667179 — intervention group
Group type: COMPARATOR
Intervention: Slowly hydrolysed starch (S)
Number of subjects: 21
Study 11129548 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone 50 mg
Number of subjects: 40
Study 11129548 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone 50 mg plus dexamethasone 0.5 mg (then 0.25 mg)
Number of subjects: 40
Study 9090948 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane/N2O/sufentanil (group A)
Number of subjects: 40
Study 9090948 — intervention group
Group type: COMPARATOR
Intervention: Propofol/N2O/sufentanil (group B)
Number of subjects: 40
Study 1874237 — intervention group
Group type: EXPERIMENTAL
Intervention: Local vibration at 60 Hz and an acceleration of 50 m·s‐2 for 5 minutes
Number of subjects: 5
Study 1874237 — intervention group
Group type: EXPERIMENTAL
Intervention: Noise at 100 dB(A) for 5 minutes
Number of subjects: 5
Study 1874237 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined exposure to local vibration at 60 Hz and noise at 100 dB(A)
Number of subjects: 5
Study 6846346 — intervention group
Group type: EXPERIMENTAL
Intervention: Training manual for pharmacists
Number of subjects: 35
Study 31573984 — intervention group
Group type: EXPERIMENTAL
Intervention: Transanal total mesorectal excision (TaTME)
Number of subjects: 101
Study 31573984 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic approach
Number of subjects: 101
Study 31573984 — intervention group
Group type: EXPERIMENTAL
Intervention: Competency Assessment Tool (CAT)
Number of subjects: 101
Study 28539093 — intervention group
Group type: EXPERIMENTAL
Intervention: Domestic violence services
Number of subjects: 4868
Study 28539093 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased levels of family engagement
Number of subjects: 4868
Study 28539093 — intervention group
Group type: COMPARATOR
Intervention: CPS response pathway (investigation or assessment)
Number of subjects: 4868
Study 28539093 — intervention group
Group type: COMPARATOR
Intervention: Service duration, intensity, and breadth
Number of subjects: 4868
Study 28539093 — intervention group
Group type: EXPERIMENTAL
Intervention: Caseworker ratings of service-need match
Number of subjects: 4868
Study 24630685 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid (ZA) 4mg intravenously every 3 months for ≤4 years
Number of subjects: 1393
Study 24630685 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard PCa therapy alone)
Number of subjects: 1393
Study 24630685 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid (ZA)
Number of subjects: 1393
Study 22908852 — intervention group
Group type: EXPERIMENTAL
Intervention: Razor
Number of subjects: 215
Study 22908852 — intervention group
Group type: COMPARATOR
Intervention: Clippers
Number of subjects: 215
Study 21627828 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol + Fluticasone Propionate (SFC)
Number of subjects: 4951
Study 21627828 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4951
Study 21627828 — intervention group
Group type: COMPARATOR
Intervention: Salmeterol alone
Number of subjects: 4951
Study 21627828 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone Propionate alone
Number of subjects: 4951
Study 21627828 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall health status deterioration
Number of subjects: 4951
Study 19396632 — intervention group
Group type: EXPERIMENTAL
Intervention: ghrelin
Number of subjects: 29
Study 19396632 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRP-6
Number of subjects: 29
Study 19396632 — intervention group
Group type: COMPARATOR
Intervention: controls
Number of subjects: 29
Study 16533451 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral misoprostol 800 mug
Number of subjects: 450
Study 16533451 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular oxytocin 10 IU
Number of subjects: 450
Study 15300538 — intervention group
Group type: EXPERIMENTAL
Intervention: N‐butylcyanoacrylate (Indermil) adhesive bonds
Number of subjects: 100
Study 15300538 — intervention group
Group type: COMPARATOR
Intervention: Polyglactin 5‐0 (Vicryl) sutures
Number of subjects: 100
Study 11059998 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy (CT)
Number of subjects: 158
Study 11059998 — intervention group
Group type: COMPARATOR
Intervention: Clinical management (CM)
Number of subjects: 158
Study 8340625 — intervention group
Group type: EXPERIMENTAL
Intervention: Lingual split method by chisel
Number of subjects: 52
Study 8340625 — intervention group
Group type: COMPARATOR
Intervention: Buccal approach with surgical bur
Number of subjects: 52
Study 8340625 — intervention group
Group type: COMPARATOR
Intervention: Both methods
Number of subjects: 52
Study 3519731 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase therapy (combined intravenous and intracoronary)
Number of subjects: 62
Study 3519731 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard coronary care unit treatment)
Number of subjects: 62
Study 3519731 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase therapy
Number of subjects: 62
Study 3519731 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 62
Study 31568390 — intervention group
Group type: EXPERIMENTAL
Intervention: Active intervention (lifestyle advice delivered by renal dietitians using behavior change techniques)
Number of subjects: 130
Study 31568390 — intervention group
Group type: COMPARATOR
Intervention: Passive intervention (leaflet advice alone)
Number of subjects: 130
Study 28865057 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard Roux-en-Y gastric bypass
Number of subjects: 113
Study 28865057 — intervention group
Group type: EXPERIMENTAL
Intervention: Distal Roux-en-Y gastric bypass
Number of subjects: 113
Study 27174526 — intervention group
Group type: EXPERIMENTAL
Intervention: Edaravone (60 mg/d) administered from the day of surgery to postsurgical day 7
Number of subjects: 72
Study 27174526 — intervention group
Group type: COMPARATOR
Intervention: Control group (no edaravone)
Number of subjects: 72
Study 27174526 — intervention group
Group type: EXPERIMENTAL
Intervention: Edaravone (60 mg/d)
Number of subjects: 72
Study 25530054 — intervention group
Group type: EXPERIMENTAL
Intervention: Pray meditation for 20 minutes using a disposable phone
Number of subjects: 160
Study 25530054 — intervention group
Group type: COMPARATOR
Intervention: Control group (phone off)
Number of subjects: 160
Study 22414705 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (a beta adrenergic antagonist)
Number of subjects: 27
Study 22414705 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sugar pill)
Number of subjects: 27
Study 22414705 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 27